Form 10-Q · Quarterly report
Albemarle Corporation 10-Q, filed Nov 4, 2026
- Filed
- CIK
- 0000915913
- Accession no.
- 0000915913-26-000129
Summary
Albemarle Corporation reported third-quarter 2026 net sales of $1.6 billion, up 19% year over year on a 39% increase in pricing, with adjusted EBITDA up 186% year over year, in its quarterly filing. The company said it expects 2026 Energy Storage sales and profitability to rise on higher lithium prices while sales volume is flat to slightly down, and that it does not expect a material direct tariff impact.
Key points
- Q3 2026 net sales were $1,553.1 million versus $1,307.8 million a year earlier, and gross profit rose to $300.7 million (19.4% margin) from $117.6 million (9.0%).
- Cash flows from operations in the first nine months of 2026 were $1.5 billion, up 64% year over year.
- Albemarle completed the sale of its controlling ownership in the Refining Solutions business and its 50% interest in the Eurecat S.A. joint venture in the first quarter of 2026 for combined pre-tax proceeds of about $648 million, and used the proceeds to repay senior notes.
- Remediation after a fire at the Talison joint venture's third chemical grade plant at Greenbushes (CGP3) has been completed, and Kemerton Trains 1 and 2 and the Chengdu conversion facilities are being placed into care and maintenance.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview We are a world leader in transforming essential resources into critical ingredients for mobility, energy, connectivity, and health. Our purpose is to enable a more resilient world. We partner to pioneer new ways to move, power, connect, and protect. The end markets we serve include grid storage, automotive, aerospace, conventional energy, electronics, construction, agriculture and food, pharmaceuticals and medical devices. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.